Repligen Corporation (RGEN)
NASDAQ
Closed
Aug 24, 2026
Day's Range
176.2852 wk Range
100.99Profile - RGEN - Repligen Corporation
Profile
Mic Code
XNGS
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1.77K
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems to support the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Headquartered in Waltham, Massachusetts, it serves biopharmaceutical drug developers, contract development and manufacturing organizations (CDMOs), and other life science companies across North America, Europe, and Asia Pacific. The company offers products in four main categories: filtration and fluid management, its largest segment; chromatography, including OPUS pre-packed columns and high-performance resins like AVIPure HiPer for viral vectors; proteins, such as Protein A ligands and affinity chromatography components; and process analytics, featuring slope spectroscopy systems like SoloVPE and FlowVPE. Repligen's technologies enable purification, cell culture growth, and process monitoring, addressing key needs in biologics production for next-generation modalities like gene therapy.
Profile Details
Type
Common Stock
Ceo
Mr. Olivier Loeillot
Address
Building 1
City
Waltham
State
MA
Zip
02453
Country
United States
Phone
781 250 0111
Key Executives - RGEN - Repligen Corporation
Key executives
Cross Listings - RGEN - Repligen Corporation
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
